← Back to Search

LY3871801 (Part B) for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose on day 1 up to postdose on day 17

Awards & highlights

Study Summary

This trial aims to assess the safety and tolerability of a drug (LY3871801) in healthy Asian and Non-Asian participants. It also looks at how the body processes the drug.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose on day 1 up to postdose on day 17

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose on day 1 up to postdose on day 17

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 up to postdose on day 17 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary outcome measures

PK: Area Under the Concentration Versus Time Curve (AUC) of LY3871801

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3871801

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3871801 (Part B)Experimental Treatment1 Intervention

LY3871801 administered orally in Chinese Participants.

Group II: LY3871801 (Part A)Experimental Treatment1 Intervention

LY3871801 administered orally in Japanese and Non-Asian Participants.

Group III: Placebo (Part B)Placebo Group1 Intervention

Placebo administered orally in Chinese Participants.

Group IV: Placebo (Part A)Placebo Group1 Intervention

Placebo administered orally in Japanese and Non-Asian Participants.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3871801

2022

Completed Phase 1

~90

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor

2,620 Previous Clinical Trials

3,216,567 Total Patients Enrolled

Study DirectorEli Lilly and Company

1,348 Previous Clinical Trials

415,713 Total Patients Enrolled

Media Library

LY3871801 (Part B) Clinical Trial Eligibility Overview. Trial Name: NCT05960851 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Would I qualify to be part of this medical research?

"Qualified participants for this medical trial should be between 18-65 years of age and have a healthy constitution. Presently, 32 people are sought after to partake in the study."

Answered by AI

Has LY3871801 (Part A) received the endorsement of the Food and Drug Administration?

"Since this is a Phase 1 trial, the data regarding LY3871801's (Part A) safety has not been exhaustively examined and thus it received a score of 1."

Answered by AI

Are individuals over 40 accepted in this experiment?

"Applicants aged 18 to 65 are eligible for this particular investigation. There is a total of 55 trials available for younger participants and 380 clinical studies designed for seniors."

Answered by AI

Could individuals currently enroll in this clinical experiment?

"Data available on clinicaltrials.gov implies that this medical trial is not actively accepting participants, despite first being posted and updated on the 9th of August 2023 and 18th of July 2023 respectively. On a brighter note, 806 other trials are currently recruiting patients nationwide."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

2023. "A Study of LY3871801 in Healthy Asian and Non-Asian Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05960851.